Observational studyJournal of neurology2025
Analysis of the Italian cohort of late-onset Pompe disease (LOPD) patients after 10 and 15 years of therapy with alglucosidase alfa.
Observational study in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-Life Effectiveness After Switching to Avalglucosidase Alfa in Late-Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study.European journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLate-onset Pompe disease (LOPD) is the first genetic neuromuscular disease treated with enzyme replacement therapy (ERT) in 2006, with variable results over time. This study aimed to assess therapeutic efficacy and safety in a large national cohort of patients after 10 and 15 years of treatment with alglucosidase alfa, all of them regularly evaluated in expert Centers.
methodsThis retrospective study analyzed data from 15 Italian Centers, examining clinical-genetic features and motor and respiratory outcomes at baseline, 10 years (T10, n = 85), and 15 years (T15, n = 42) after ERT initiation. Patients were categorized by baseline 6-min walk test (6MWT: 1: < 150 m, 2: 150-299 m, 3: 300-449 m, 4: ≥ 450 m) or forced vital capacity (FVC: 0: < 80%, 1: ≥ 80%) to assess outcome differences based on initial functional status.
resultsAll patients were ambulant at baseline. Motor performance, assessed by 6MWT, declined across all functional groups, but even the lowest-performing patients at baseline (Groups 1-2) were mostly ambulant by T15 (50% and 71% respectively). In the best performing patients at baseline (Group 4), subjects maintained quite high performance values also at T15, with a statistically significant decrement observed at T10, and a stabilization at T15; none of them lost ambulation at T15. Despite an overall FVC% reduction, 21/42 patients (50%) remained ventilator-free at T15. No ERT discontinuations or significant adverse events were reported.
conclusionAlglucosidase alfa therapy showed variable results in a long-term perspective, confirming a reduction in mortality in all functional groups, and stabilization in several patients, without relevant safety concerns. Motor and respiratory function responses varied by functional groups and in single patients, underscoring the need for additional outcome measures. These long-term results will be useful for comparing the possible prolonged efficacy of the new therapies for Pompe disease.
Indexed as
Identifiers
40643754What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.